These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 18818391)

  • 1. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
    Jabbour E; Kantarjian HM; Jones D; Reddy N; O'Brien S; Garcia-Manero G; Burger J; Cortes J
    Blood; 2008 Dec; 112(13):4839-42. PubMed ID: 18818391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
    Jabbour E; Jones D; Kantarjian HM; O'Brien S; Tam C; Koller C; Burger JA; Borthakur G; Wierda WG; Cortes J
    Blood; 2009 Sep; 114(10):2037-43. PubMed ID: 19567878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
    Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
    Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
    Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
    Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
    Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
    Jabbour E; Branford S; Saglio G; Jones D; Cortes JE; Kantarjian HM
    Cancer; 2011 May; 117(9):1800-11. PubMed ID: 21509757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
    Guilhot F; Apperley J; Kim DW; Bullorsky EO; Baccarani M; Roboz GJ; Amadori S; de Souza CA; Lipton JH; Hochhaus A; Heim D; Larson RA; Branford S; Muller MC; Agarwal P; Gollerkeri A; Talpaz M
    Blood; 2007 May; 109(10):4143-50. PubMed ID: 17264298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
    Branford S; Melo JV; Hughes TP
    Blood; 2009 Dec; 114(27):5426-35. PubMed ID: 19880502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
    Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
    Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.
    Ribeiro BF; Miranda EC; Albuquerque DM; Delamain MT; Oliveira-Duarte G; Almeida MH; Vergílio B; Silveira RA; Oliveira-Duarte V; Lorand-Metze I; De Souza CA; Pagnano KB
    Clinics (Sao Paulo); 2015 Aug; 70(8):550-5. PubMed ID: 26247667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
    Hochhaus A; Kantarjian HM; Baccarani M; Lipton JH; Apperley JF; Druker BJ; Facon T; Goldberg SL; Cervantes F; Niederwieser D; Silver RT; Stone RM; Hughes TP; Muller MC; Ezzeddine R; Countouriotis AM; Shah NP
    Blood; 2007 Mar; 109(6):2303-9. PubMed ID: 17138817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
    Jabbour E; Kantarjian H
    Am J Hematol; 2012 Nov; 87(11):1037-45. PubMed ID: 23090888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.
    Parker WT; Lawrence RM; Ho M; Irwin DL; Scott HS; Hughes TP; Branford S
    J Clin Oncol; 2011 Nov; 29(32):4250-9. PubMed ID: 21990409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
    Jabbour E; Kantarjian H; Cortes J
    Semin Hematol; 2010 Oct; 47(4):344-53. PubMed ID: 20875551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Schiffer CA
    N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
    [No Abstract]   [Full Text] [Related]  

  • 16. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
    Jabbour E; Hochhaus A; Cortes J; La Rosée P; Kantarjian HM
    Leukemia; 2010 Jan; 24(1):6-12. PubMed ID: 19798095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
    Kwan TK; Ma ES; Chan YY; Wan TS; Liu HS; Sim JP; Yeung YM; Lie AK; Yip SF
    Hong Kong Med J; 2009 Oct; 15(5):365-73. PubMed ID: 19801694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
    Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
    Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia].
    Jiang Q; Qin Y; Lai Y; Jiang H; Shi H
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):7-13. PubMed ID: 26876246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.